TAP Licenses Investigational PPI As Part Of Gastroenterological Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
New investigational proton pump inhibitor, licensed from Seoul, Korea-based Ilyang, will enter Phase II trials in 2006, TAP reports.
You may also be interested in...
TAP Licenses Prevacid To Novartis For 2009 Switch
TAP plans to continue sale of prescription lansoprazole “at least” until the compound patent expires.
TAP Licenses Prevacid To Novartis For 2009 Switch
TAP plans to continue sale of prescription lansoprazole “at least” until the compound patent expires.
Prevacid Follow-On NDA To Be Submitted In 2008
TAP is preparing to start Phase III clinical trials for TAK-390MR, an enantiomer of Prevacid (lansoprazole).